Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cytotherapy. 2014 Feb;16(2):149-59. doi: 10.1016/j.jcyt.2013.11.010.

The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care.

Author information

  • 1Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
  • 2Program for Cell Enhancement and Technologies for Immunotherapy, Sheikh Zayed Institute for Pediatric Surgical Innovation, and Center for Cancer and Immunology Research, Children's National Medical Health System, Washington, DC, USA.
  • 3Program for Cell Enhancement and Technologies for Immunotherapy, Sheikh Zayed Institute for Pediatric Surgical Innovation, and Center for Cancer and Immunology Research, Children's National Medical Health System, Washington, DC, USA. Electronic address: cbollard@childrensnational.org.

Abstract

Adoptive immunotherapy-in particular, T-cell therapy-has recently emerged as a useful strategy with the potential to overcome many of the limitations of antiviral drugs for the treatment of viral complications after hematopietic stem cell transplantation. In this review, we briefly summarize the current methods for virus-specific T-cell isolation or selection and we report results from clinical trials that have used these techniques, focusing specifically on the strategies aimed to broaden the application of this technology.

Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

T cell; immunotherapy; stem cell transplantation; virus

PMID:
24438896
[PubMed - indexed for MEDLINE]
PMCID:
PMC3928596
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk